


**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

1-20. (Cancelled)

21. (Currently amended) A compound of formula (I)



(I)


wherein

R is ~~a nitrogen containing one or two ring moiety consisting of one or two aromatic rings~~ ~~pyridyl, optionally mono- or disubstituted independently by C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, halogen, trihalogenomethyl, methylthio, nitro, cyano, C<sub>2-5</sub> alkoxy carbonyl or carboxamido; p-tolylsulfonyl;~~

~~R<sub>1a</sub>-CH<sub>2</sub> where R<sub>1a</sub> is hydrogen, C<sub>1-4</sub> alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, thienyl, furyl or p-tolylsulfonyl—optionally independently substituted with one or more C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or~~


~~R<sub>1b</sub>-CO, where R<sub>1b</sub> is C<sub>1-4</sub> alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, optionally independently substituted with one or more C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or R<sub>1b</sub> is mono- or disubstituted amino, or a saturated N-containing heterocyclic group~~ piperidino;

B is a group of formula (1), (2), (3), or (4)



and

Z is a group of formula (A), (B), (C), (D), (E), or (F);



or a salt, isomer, tautomer, or hydrate or solvate thereof.

22. (Canceled).

23. (Currently amended) AThe compounds according to Claim 2221 wherein

R is ~~pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pirazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzimidazolyl, indazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl or benzisoxazolyl~~ optionally independently mono- or disubstituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, halogen, trihalogenomethyl, methylthio, nitro, or cyano; p-tolylsulfonyl; R<sub>1a</sub>-CH<sub>2</sub>, where R<sub>1a</sub> is ~~hydrogen, C1-4 alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, thienyl, furyl or p-tolylsulfonyl~~ optionally independently substituted with one or more C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or R<sub>1b</sub>-CO where R<sub>1b</sub> is ~~C1-4 alkyl, phenyl, benzyl, phenylethyl, phenylethenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl~~ optionally independently substituted with one or more C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, alkylenedioxy, halogen, trihalogenomethyl, nitro or cyano; or R<sub>1b</sub> is ~~mono- or disubstituted amino, or a saturated N-containing heterocyclic group containing pyrrolidine, piperidino, piperazine or morpholine~~; or a salt, isomer, tautomer, or hydrate thereof.

24. (Currently amended) AThe compound according to Claim 2221 wherein

R is ~~pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, or benzisoxazolyl~~ optionally independently mono- or disubstituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, halogen, nitro, cyano, C<sub>2-5</sub> alkoxycarbonyl or carboxamido; p-tolylsulfonyl; R<sub>1a</sub>-CH<sub>2</sub> where R<sub>1a</sub> is ~~benzyl or phenylethenyl~~ optionally independently substituted with one or more C<sub>1-4</sub> alkyl or alkylenedioxy; or R<sub>1b</sub>CO where R<sub>1b</sub> is ~~phenyl, benzyl, phenylethyl, or phenylethenyl~~ optionally substituted with alkylenedioxy, or R<sub>1b</sub> is piperidino; and

Z is a group of formula (A) or formula (B);

or a salt, isomer, tautomer, or hydrate thereof.

25. (Currently amended) AThe compound according to Claim 24 wherein

R is ~~pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, or benzisoxazolyl~~ optionally independently mono- or disubstituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, halogen, nitro, or cyano; p-tolylsulfonyl;

R<sub>4a</sub>-CH<sub>2</sub> wherein R<sub>4a</sub> is benzyl or phenylethethyl optionally independently substituted with one or more C1-4 alkyl or alkyleneoxy; or  
R<sub>1b</sub>CO where R<sub>1b</sub> is phenyl, benzyl, phenylethyl, or phenylethethyl optionally independently substituted with alkyleneoxy; or R<sub>1b</sub> is piperidino;  
or a salt, isomer, tautomer, or hydrate thereof.

26. (Currently amended) Athe compound according to Claim 25 wherein R is pyrimidinyl, pyridyl, or pyrazinyl substituted with nitro or cyano, and B is a group of formula (1) or (2); or a salt, isomer, tautomer, or hydrate thereof.

27. (Currently amended) A compound selected from the group consisting of:

(4R)-3-(2-{{8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl}-exo-amino}acetyl)thiazolidine-4-carbonitrile;

(4R)-3-(2-{{8-(5-Cyanopyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl}-exo-amino}acetyl)thiazolidine-4-carbonitrile;

(4R)-3-(2-{{8-(5-Cyanopyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl}-endo-amino}acetyl)thiazolidine-4-carbonitrile;

(4R)-3-(2-{{8-(2-Pyrazinyl)-8-azabicyclo[3.2.1]octan-3-yl}-exo-amino}acetyl)thiazolidine-4-carbonitrile;  
and

(2S)-1-(2-{{8-(5-Nitropyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl}-exo-amino}acetyl)pyrrolidine-2-carbonitrile;

or a salt, or hydrate, or solvate thereof.

28. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 21 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

29. (Canceled)

30. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 23 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.


31. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 24 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

32. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 25 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

33. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 26 or a salt, isomer, tautomer, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.


34. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 27 or a salt, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

35. (Currently amended) A process for the preparation of preparing the compounds of a compound according to Claim 21 which comprises reacting a compound of formula (II)



(II)

with a compound of formula (III)



(III)

wherein in the above formulas R, B, and Z are as defined in Claim 21.

36-43. (Canceled)


44. (Currently amended) A compound of the formula



wherein

R is a nitrogen containing one or two ring moiety consisting of one or two aromatic rings pyridyl, optionally mono- or disubstituted independently by C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, halogen, trihalogenomethyl, methylthio, nitro, cyano, C<sub>2-5</sub> alkoxy carbonyl or carboxamido; p-tolylsulfonyl;

B is a group of formula (1), (2), (3), or (4)



Y is hydrogen or tert-butoxycarbonyl;  
or a salt thereof.

45. (Canceled)